Search Within

Jennifer Kimberly Lue

Formats
  1. Meeting Abstract (31)
  2. Journal Article (8)
  3. Book Section (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Department of Medicine (37)
  2. Hematologic Malignancies, Division of (37)
  3. Center for Hematologic Malignancies (35)
  4. Lymphoma (35)
  5. Hematology-Oncology Fellows (31)
  6. GSK Faculty (28)

More Groups

People
  1. Gilles Salles (37)
  2. Lorenzo Falchi (34)
  3. Andrew Zelenetz (32)
  4. Anita Kumar (32)
  5. Maria Palomba (32)
  6. Paul Hamlin (28)

More People

Years
  1. 2025 (3)
  2. 2024 (17)
  3. 2023 (19)
  4. 2022 (5)
Publications
  1. Blood (28)
  2. Hematological Oncology (3)
  3. Blood Advances (2)
  4. Haematologica (2)
  5. Journal of Clinical Oncology (2)
  6. Leukemia and Lymphoma (2)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. Wiley Blackwell (5)
  3. American Society of Clinical Oncology (2)
  4. Ferrata Storti Foundation (2)
  5. Taylor & Francis Group (2)
  6. Elsevier Inc. (1)

More Publishers

Results (44)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes
    Meeting Abstract

    Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study
    Meeting Abstract

    Lue, J. K.; Morschhauser, F.; Tilly, H.; Lenz, G.; Jardin, F.; Herrera, A. F.; Sharman, J. P.; Flowers, C.; Friedberg, J. W.; Trneny, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma
    Journal Article

    Ryu Tiger, Y. K.; Jain, S.; Barta, S. K.; Tolu, S.; Estrella, B.; Sawas, A.; Lue, J. K.; Francescone, M. M.; Pro, B.; Amengual, J. E.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Pharmacology to practice: The similarities and differences of drugs targeting CD20
    Book Section

    Lue, J. K.; Cheson, B. D.
    In O'Connor, O. A.; Ansell, S. M.; Gribben, J. G. (Eds.) Precision Cancer Therapies: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice (2024)

    Fulltext@MSK | Save